PortfoliosLab logoPortfoliosLab logo
RIGL vs. SE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

RIGL vs. SE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rigel Pharmaceuticals, Inc. (RIGL) and Sea Limited (SE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, RIGL achieves a -23.30% return, which is significantly higher than SE's -34.98% return.


RIGL

1D
2.40%
1M
2.24%
YTD
-23.30%
6M
-19.45%
1Y
54.23%
3Y*
27.10%
5Y*
-3.96%
10Y*
3.28%

SE

1D
-3.21%
1M
-11.31%
YTD
-34.98%
6M
-33.66%
1Y
-46.36%
3Y*
8.08%
5Y*
-21.47%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

RIGL vs. SE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
RIGL
Rigel Pharmaceuticals, Inc.
-23.30%154.64%16.00%-3.33%-43.40%-24.29%63.55%-6.96%-40.72%-2.27%
SE
Sea Limited
-34.98%20.24%161.98%-22.16%-76.74%12.39%394.90%255.30%-15.08%-17.97%

Correlation

The correlation between RIGL and SE is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.13

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2017

0.23

The correlation between RIGL and SE shifts across timeframes, from 0.13 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

RIGL:

$646.69M

SE:

$52.76B

EPS

RIGL:

$19.21

SE:

$2.57

PE Ratio

RIGL:

1.71

SE:

32.21

PEG Ratio

RIGL:

0.00

SE:

0.15

PS Ratio

RIGL:

2.08

SE:

2.06

PB Ratio

RIGL:

1.62

SE:

4.11

Total Revenue (TTM)

RIGL:

$299.77M

SE:

$25.19B

Gross Profit (TTM)

RIGL:

$279.95M

SE:

$11.15B

EBITDA (TTM)

RIGL:

$125.80M

SE:

$2.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

RIGL vs. SE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RIGL
RIGL Risk / Return Rank: 6767
Overall Rank
RIGL Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
RIGL Sortino Ratio Rank: 7070
Sortino Ratio Rank
RIGL Omega Ratio Rank: 6969
Omega Ratio Rank
RIGL Calmar Ratio Rank: 6565
Calmar Ratio Rank
RIGL Martin Ratio Rank: 6161
Martin Ratio Rank

SE
SE Risk / Return Rank: 1010
Overall Rank
SE Sharpe Ratio Rank: 77
Sharpe Ratio Rank
SE Sortino Ratio Rank: 88
Sortino Ratio Rank
SE Omega Ratio Rank: 88
Omega Ratio Rank
SE Calmar Ratio Rank: 1313
Calmar Ratio Rank
SE Martin Ratio Rank: 1313
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RIGL vs. SE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Rigel Pharmaceuticals, Inc. (RIGL) and Sea Limited (SE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


RIGLSEDifference
Sharpe ratioReturn per unit of total volatility

+1.70

Sortino ratioReturn per unit of downside risk

+3.02

Omega ratioGain probability vs. loss probability

1.20

0.83

+0.37

Calmar ratioReturn relative to maximum drawdown

1.09

-0.77

+1.86

Martin ratioReturn relative to average drawdown

1.91

-1.27

+3.17

RIGL vs. SE - Sharpe Ratio Comparison

The current RIGL Sharpe Ratio is 0.78, which is higher than the SE Sharpe Ratio of -0.92. The chart below compares the historical Sharpe Ratios of RIGL and SE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

RIGL vs. SE - Drawdown Comparison

The maximum RIGL drawdown since its inception was -99.37%, which is greater than SE's maximum drawdown of -90.51%. Use the drawdown chart below to compare losses from any high point for RIGL and SE.


Loading charts...

Drawdown Indicators


RIGLSEDifference

Max Drawdown

Largest peak-to-trough decline

-99.37%

-90.51%

-8.86%

Max Drawdown (1Y)

Largest decline over 1 year

-50.08%

-60.22%

+10.14%

Max Drawdown (3Y)

Largest decline over 3 years

-57.75%

-60.22%

+2.47%

Max Drawdown (5Y)

Largest decline over 5 years

-85.24%

-90.51%

+5.27%

Max Drawdown (10Y)

Largest decline over 10 years

-86.40%

Current Drawdown

Current decline from peak

-96.93%

-77.40%

-19.53%

Average Drawdown

Average peak-to-trough decline

-90.91%

-44.10%

-46.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.64%

36.57%

-7.93%

Volatility

RIGL vs. SE - Volatility Comparison

The current volatility for Rigel Pharmaceuticals, Inc. (RIGL) is 12.05%, while Sea Limited (SE) has a volatility of 14.69%. This indicates that RIGL experiences smaller price fluctuations and is considered to be less risky than SE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


RIGLSEDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.05%

14.69%

-2.64%

Volatility (6M)

Calculated over the trailing 6-month period

36.64%

38.05%

-1.41%

Volatility (1Y)

Calculated over the trailing 1-year period

69.89%

50.74%

+19.15%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.46%

64.13%

+21.33%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

82.81%

62.59%

+20.22%

Dividends

RIGL vs. SE - Dividend Comparison

Neither RIGL nor SE has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

RIGL vs. SE - Financials Comparison

This section allows you to compare key financial metrics between Rigel Pharmaceuticals, Inc. and Sea Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.002.00B4.00B6.00B8.00B20222023202420252026
58.82M
7.10B
(RIGL) Total Revenue
(SE) Total Revenue
Values in USD except per share items

RIGL vs. SE - Profitability Comparison

The chart below illustrates the profitability comparison between Rigel Pharmaceuticals, Inc. and Sea Limited over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

40.0%50.0%60.0%70.0%80.0%90.0%100.0%20222023202420252026
92.2%
44.3%
Portfolio components
RIGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a gross profit of 54.21M and revenue of 58.82M. Therefore, the gross margin over that period was 92.2%.

SE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sea Limited reported a gross profit of 3.15B and revenue of 7.10B. Therefore, the gross margin over that period was 44.3%.

RIGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported an operating income of 11.89M and revenue of 58.82M, resulting in an operating margin of 20.2%.

SE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sea Limited reported an operating income of 565.39M and revenue of 7.10B, resulting in an operating margin of 8.0%.

RIGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Rigel Pharmaceuticals, Inc. reported a net income of 8.65M and revenue of 58.82M, resulting in a net margin of 14.7%.

SE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sea Limited reported a net income of 427.94M and revenue of 7.10B, resulting in a net margin of 6.0%.


Frequently Asked Questions


RIGL and SE have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SE has higher volatility (14.69%) compared to RIGL (12.05%). In terms of maximum drawdown, RIGL dropped -99.37% vs SE's -90.51%.

RIGL currently has the higher Sharpe Ratio (0.78 vs -0.92), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for RIGL and SE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer